RESOURCES

From Lab to Clinic: How RXFP1-Humanized Mice are Paving the Way for Next-Generation Cardiovascular Therapeutics

The relaxin receptor RXFP-1 plays a pivotal role in cardiovascular health. Widely expressed in the heart, kidneys, and blood vessels, RXFP-1 is activated by relaxin, an endogenous heterodimeric insulin-like peptide. Beyond regulating cardiovascular functions such as renal blood flow, relaxin exerts anti-fibrotic, anti-inflammatory, and angiogenic effects, positioning the RXFP-1 pathway as a promising therapeutic target for conditions including heart failure and liver fibrosis.

Unlocking the Potential of Antibody-Drug Conjugates: GemPharmatech’s Comprehensive In Vitro Evaluation Platform

Antibody-drug conjugates (ADCs) represent a rapidly advancing therapeutic class for both solid tumors and hematological malignancies. Unlike conventional monoclonal antibodies, ADCs combine a tumor-targeting antibody with a highly potent cytotoxic payload, enabling selective drug delivery to cancer cells. At GemPharmatech, we provide integrated end-to-end preclinical solutions to support ADC development. These solutions center around an advanced in vitro platform as well as in vivo capabilities to support every step of ADC functional assessment

Advance Psoriatic Arthritis Drug Discovery with a Validated Preclinical Model for JAKi and Dexamethasone Testing

August is Psoriasis Awareness Month, a time to raise awareness for psoriasis, a chronic immune-mediated skin condition marked by erythematous plaques, scaling, and dysregulated keratinocyte proliferation.However, the burden can extend beyond the skin. Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA), a progressive inflammatory disease affecting the joints.

Advancing Alzheimer's Research at AAIC 2025: Discover GemPharmatech's Cutting-Edge AD Mouse Models

The Alzheimer's Association International Conference (AAIC 2025) is the premier global forum for groundbreaking research in Alzheimer's disease (AD) and dementia. As a leader in preclinical models, GemPharmatech is proud to showcase our advanced AD mouse models at this year's conference. Join us to explore how our innovative tools can accelerate your research and drive the next wave of therapeutic breakthroughs.

TCE In Vitro Evaluation Platform: Comprehensive Assessment from Target Engagement to Tumor Cell Killing

Bispecific T-cell engagers (TCEs) are engineered antibodies that simultaneously bind tumor-associated antigens (TAAs) on tumor cells and the CD3 receptor on T-cells to direct potent cytotoxic responses against cancer cells. At GemPharmatech, we have established a comprehensive in vitro platform to support development of TCE-based therapies from evaluating binding efficiency to functional activation, and immune cell mediated killing across multiple assay formats.

Weight Loss of 10% Within 2 Weeks? Evaluating Amylin Analogs in Diet-Induced Obese (DIO) Rat Model

Cagrilintide, a long-acting amylin analog, demonstrates transformative potential in obesity treatment. Studies reveal species-specific effects: amylin analogs induce sustained weight loss in rats but exhibit weaker anorectic effects in mice. Leveraging this divergence, GemPharmatech employed a diet-induced obese (DIO) rat model (12-week high-fat diet [HFD] induction) to test a 4-week intervention. Read the full blog to learn more.

World Vitiligo Day: Advancing Awareness and Therapeutic Innovation

Vitiligo is an acquired depigmenting skin disorder affecting 0.5%-2% of the global population. Current treatments include glucocorticoids and calcineurin inhibitors (e.g., tacrolimus ointment, pimecrolimus cream). However, efficacy is often partial and relapse rates remain high. At GemPharmatech, we provide two distinct immunodeficient mouse models of vitiligo to support early-stage drug efficacy and translational research. These models enable in vivo testing of candidate therapies, from small molecules to biologics, under controlled immunological contexts.

B Cell Depletion Therapy: A New Approach to the Treatment of Autoimmune Diseases

World Parkinson’s Day 2025: Advancing Parkinson’s Research with Cutting-Edge Mouse Models

April 11th marks World Parkinson’s Day, honoring James Parkinson, the pioneering physician who first systematically described the disease carrying his namesake. Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting millions worldwide, primarily impairing motor functions and often accompanied by cognitive decline. As the second most common neurodegenerative disease globally, its prevalence is projected to double by 2050, reaching more than 25 million patients. This growth underscores the urgent need for breakthroughs in understanding and treating PD.